prof. dr. E.G.E. (Elisabeth) de Vries


No picture available


  1. Qiu, S-Q. (2019). Optimizing the treatment strategy of breast cancer. [Groningen]: Rijksuniversiteit Groningen.
  2. Heijink, A. M. (2018). Cell fate after DNA damage. [Groningen]: Rijksuniversiteit Groningen.
  3. Warnders, J. F. (2018). Preclinical molecular imaging to study the biodistribution of antibody derivatives in oncology. [Groningen]: Rijksuniversiteit Groningen.
  4. van den Brom, R. R. H. (2017). New approaches and consequences for elderly cancer patients with focus on melanoma. [Groningen]: Rijksuniversiteit Groningen.
  5. Pool, M. (2017). Preclinical molecular imaging of target expression and target dynamics in cancer. [Groningen]: Rijksuniversiteit Groningen.
  6. Wieringa, H. (2017). Targeting the DNA damage response in cervical cancer. [Groningen]: Rijksuniversiteit Groningen.
  7. Lamberts, L. E. (2016). Antibody imaging as biomarker in early cancer drug development and treatment. [Groningen]: Rijksuniversiteit Groningen.
  8. van Kruchten, M. (2015). Molecular imaging of estrogen receptors. [Groningen]: University of Groningen.
  9. Arjaans, M. (2015). Preclinical targeting of the tumor microenvironment: Possibilities and consequences. [Groningen]: University of Groningen.
  10. den Hollander, M. W. (2015). Targeted therapy, molecular imaging and biomarkers in cancer treatment: Getting more personalized. [Groningen]: University of Groningen.
  11. Gaykema, S. (2014). Optimizing cancer therapy: a focus in molecular imaging. [S.l.]: [S.n.].
  12. Weide, K. V. D. (2011). The use of statins in acute myeloid leukemia. Groningen: s.n.
  13. Koopmans, K. P. (2008). Metabolic PET tracers for neuroendocrine tumors. [S.l.]: [s.n.].
  14. Mom, C. H. (2007). Exploring targeted therapies in oncology. [S.l.]: [s.n.].
  15. Schaapveld, M. (2005). Breast cancer: patterns of care, second cancers and genetics. Groningen: s.n.
  16. Zoodsma, M. (2005). Genetic susceptibility of cervical cancer. [S.n.].
Previous 1 2 Next

ID: 162081